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1. INTRODUCTION & PURPOSE 
This document details the rules proposed and the presentation that will be followed, as 
closely as possible, when analysing and reporting the main results from the STAR Trial. 
The purpose of the plan is to:  
1. Ensure that the analysis is appropriate for the aims of the trial, reflects good statistical 
practice, and that interpretation of a priori and post hoc analyses respectively is 
appropriate. 
2. Explain in detail how the data will be handled and analysed to enable others to 
perform the actual analysis in the event of sickness or other absence. 
3. Protect the project by helping it keep to timelines and within scope. 
 
Additional exploratory or auxiliary analyses of data not specified in the protocol are 
permitted but fall outside the scope of this analysis plan (although such analyses would be 
expected to follow Good Statistical Practice). 
The analysis strategy will be made available if required by journal editors or referees 
when the main papers are submitted for publication.  Additional analyses suggested by 
reviewers or editors will, if considered appropriate, be performed in accordance with the 
Analysis Plan, but if reported the source of such a post-hoc analysis will be declared. 
 
Editorial changes 
Amendments to the statistical analysis plan will be described and justified in the final report 
of the trial in Table 52 of this document. 
Tables and figures 
Throughout this document references are made to any skeleton tables and figures to be used 
in the reporting of the trial (e.g. Figure F1 or Table T1). Such tables and figures can be found 
in Appendix A of this document, and are intended as a guide for trial reporting. Final versions 
of the tables/figures may differ: tables may be combined, and/or their layout or numbering 
may evolve. However, the content will be consistent with Appendix A. 
In this document, references to the protocol refer to “version 3, 06-02-2017”. 
2. TRIAL BACKGROUND AND OBJECTIVES 
2.1 Background 
 
Please refer to the trial protocol, section titled “Background”. 
2.2. Trial objectives and aims 
Please refer to the trial protocol, section titled “Aims and Objectives”. 
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3.  TRIAL DESIGN AND PROCEDURES 
3.1. Trial design and configuration 
Please refer to the trial protocol, section titled “Overview of trial design”, in the subsection 
titled “Main trial”. 
3.2. Trial centres 
Please refer to the trial protocol, section titles “Patient selection and recruitment”. 
3.3. Selection criteria 
Please refer to the trial protocol, section titled “Selection criteria”. 
3.4. Description of interventions 
Please refer to the trial protocol, section titled “Intervention: STAR Care Pathway”. 
 
3.5. Control: Care as usual 
 
Please refer to the trial protocol, section titled “Control: Usual Care”. 
3.6. Randomisation procedures 
After patients have provided written, informed consent to participate and have completed 
and returned a baseline questionnaire, they will be randomly allocated to the STAR pathway 
or usual care. Randomisation will occur as soon as possible after the baseline questionnaire 
is received by the research team. Randomisation with allocation concealment will be 
conducted remotely via the Bristol Randomised Trials Collaboration using a web-based 
randomisation system. Randomisation will take place on a 2:1 basis to ensure that the 
intervention service is running at sufficient capacity to enable a pragmatic assessment of its 
effectiveness and, particularly, cost-effectiveness. If the intervention is operating to a 
sufficient degree of capacity per-protocol and CACE analyses will be more reliable and have 
higher power. To ensure reasonable balance between the two treatment groups, allocation 
will be minimised by pain in the replaced knee (assessed with both the Brief Pain Inventory 
Severity and the Brief Pain Inventory Interference Scales – these scores are both categorised 
using tertiles of STAR PACE data for these scores), and stratified by orthopaedic centre 
(Bristol, Cardiff, Exeter or Oxford). Randomisation will be performed by a member of the 
research team and the local researcher at each site will then inform participants of the 
result. 
3.7. Sample size and justification 
We estimate that 20% of patients who have had primary total knee replacement will have 
long-term post-surgical pain. Based on our recent trial in total knee replacement (Wylde V, 
2015), we estimate conservatively that we will achieve a recruitment rate of 40%. Surgical 
audit data show that the four trial centres conduct over 1,900 primary total knee 
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replacement procedures annually. Over 30 months, this equates to 4,750 procedures, and 
we estimate that 950 of these patients will have long-term post-surgical pain. With a 
recruitment rate of 40% we can recruit 380 patients over this period. In our recent trial we 
achieved 83% follow-up (Marques EM, 2015); therefore, allowing for a generous 25% loss to 
follow-up in the STAR trial, a total of 380 participants randomised would yield 285 for 
analysis. For a 2:1 intervention: control randomisation ratio we would have a power of 80% 
to 90% to detect standardised differences of between 0.35 to 0.40 standard deviations (SDs) 
using a 2-sided 5% significance level. From previous studies (Dworkin RH, 2008),(Bruce J, 
2014), the SDs for each of the BPI Interference and Pain Severity scales for patients with 
long-term post-surgical pain has been observed to be approximately 2, in which case the 
target effect size translates to a difference between intervention and control groups of 
between 0.7 and 0.8 scale points for both scales. Such a difference would be worthwhile 
detecting clinically, since the current consensus statement indicates that differences of 
approximately one scale point can be deemed the minimally important difference for both 
of these scales (Bruce J, 2014),(Kroenke K, 2009). 
3.8. Blinding and breaking of blind 
Please refer to the trial protocol, section titled “Blinding”. 
3.9. Trial committees 
Please refer to the trial protocol, section titled “Trial organisation and oversight”. 
3.10. Outcome measures 
Please refer to the trial protocol, section titled “Outcome measures”. 
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4. GENERAL ANALYSIS CONSIDERATIONS 
4.1. Analysis populations 
The primary analysis of the data will be on a complete case basis, in accordance as far as 
possible with the intention to treat (ITT) principle whereby we analyse as randomised, 
disregarding protocol deviations or non-compliance. Sensitivity analyses will utilise 
imputation methods to handle missing data to ascertain whether their exclusion in the 
primary analysis has had any effect within an ITT paradigm. In addition, a crude per protocol 
analysis will be performed using those patients who adhered with the intervention 
sufficiently. Adherence to the intervention, for a patient in the intervention arm, is defined 
as the patient attending their assessment clinic appointment and for patients in the control 
arm, adherence cannot be measured as they adhere by using usual care. We assume that all 
patients in the control arm have adhered to the intervention allocation. This per protocol 
analysis will address the same points as the ITT analysis just using a different population. 
Since these results are likely to be biased, we will also use the Complier Average Causal 
Effect (CACE) approach to adjust for any selection effects in terms of adherence. 
 
 
4.2. Derived variables 
 
Co-primary outcome measures  
 
The Brief Pain Inventory is a questionnaire which consists of 14 questions. Eleven of which 
are included in Section A of the follow-up questionnaire for STAR. The two scores which will 
be used as our co-primary are described below. 
 
• Pain Severity Score: The Pain Severity Score is calculated by taking the mean of the 
rating scores of the first four questions in Section A of the questionnaire 
(Q1+Q2+Q3+Q4)/4. 
• Pain Interference Score: The Pain Interference Score is calculated by taking the 
mean of the last seven questions in Section A of the questionnaire 
(Q7+Q8+Q9+Q10+Q11+Q12+Q13)/7. 
 
Secondary outcome measures 
 
• Oxford Knee Score (OKS) 
The OKS is calculated using the items in section B of the questionnaire. To calculate the OKS 
we sum the responses to the 12 items (individual items scored 0-4, worst to best). The total 
score has a range of 0-48 (worst to best). The Oxford Knee Score can be split into two sub-
scales: the pain and function subscales.  
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a.     OKS Pain subscale: the raw subscale is equal to the sum of the responses to the 
following questions: 1, 4, 5, 6, 8, 9 and 10. This is then standardised to range from 0 
to 100 by multiplying by 3.57. 
b.     OKS Function subscale: the raw subscale is equal to the sum of the responses to the 
following questions: 2, 3, 7, 11 and 12. This is then standardised to range from 0 to 
100 by multiplying by 5. 
• PainDETECT  
The PainDETECT score is calculated using items in Section C of the questionnaire. The first 
seven questions are scored zero to five (Never – Very Strong). The eighth question is a 
picture representation of the pain and these are scored between negative one and positive 
one. Lastly the ninth question is scored 2 if “Yes” is selected and zero if “No” is selected. The 
sum of each score provides the PainDETECT score. This ranges from -1 to 38 and scores fall 
into three categories: (-1 to 12) nociceptive, (13-18) unclear and (19-38) neuropathic pain.  
• DN-4 
The DN-4 score is a score out of 7 corresponding to the number of ‘yes’ answers the patient 
gave in Section D.  
• EQ-5D-5L  
The EQ-5D-5L provides a state of 5 characters ‘XXXXX’. Each of the five items in Section E 
provide an element of the state from 1 to 5. The best case scenario is 11111 which would 
mean there is no problem with each area. The worst case scenario is 55555 and this 
indicates that there are high levels of concern with all five areas (mobility, self-care, usual 
activities, pain/discomfort and anxiety/depression). The EQ-5D-5L will be used by the Health 
economics team and will not be used for Statistical analysis.  
• Short Form-12 
This outcome is derived by software using responses from Section F of the questionnaire. 
The statistician will process the data in the software to give a score which will be in the 
desired format to be analysed. 
• Hospital Anxiety and Depression Scale (HADS) 
HADS is split into two sub-scales, the Anxiety Scale and the Depression Scale. Each scale 
comprises of the sum of responses from 7 items from Section H of the questionnaire. Each 
item is scored from 0 to 3 with 0 being the best-case scenario and 3 being the worst. Each of 
the two sub-scales are categorised into a normal score (0-7); borderline anxiety/depression 
(8-10) and clinical anxiety/depression (≥11).  
• ICECAP-A  
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ICECAP-A uses responses from Section I of the questionnaire and provides a state of 5 
characters ‘XXXXX’. This then allows us to calculate a tariff value for items which make up 
the state. This tariff value is the sum of pre-specified values corresponding to the answers 
given in the questionnaire. The code for this is presented in the appendix.  
• Pain Catastrophizing Scale  
The Pain Catastrophizing Scale is split into three sub-scales, The Rumination Scale, The 
Magnification Scale and The Helplessness Scale. Each scale is a sum of the ratings given to 
each of the following items of Section J of the questionnaire: 
1. The Rumination Scale: 8, 9, 10, 11  
2. The Magnification Scale: 6, 7, 13 
3. The Helplessness Scale: 1, 2, 3, 4, 5, 12 
The whole scale is additive of the three subscales and will be used for primary analysis 
however we will also explore analysis of the individual sub scales. 
 
• Pain Solutions Questionnaire  
The Pain Solution Questionnaire is split into four sub-scales, Solving Pain, Meaningfulness of 
Life despite Pain, Acceptance of Insolubility of Pain and Belief in Solution. Each scale is a sum 
of the answers given to each of the following items of Section K of the questionnaire: 
1. Solving Pain: 7, 10, 11, 12 
2. Meaningfulness of Life despite Pain: 1, 2, 3, 8, 13 
3. Acceptance of Insolubility of Pain: 4, 5, 9 
4. Belief in Solution: 6, 14 
The four sub scales will be analysed separately. 
 
• Self-Administered Patient Satisfaction Scale for Primary Hip and Knee Arthroplasty 
The satisfaction scale is made up of the first four questions of Section L. Items are scored on 
a 4-point Likert scale with response categories consisting of very satisfied (100 points), 
somewhat satisfied (75 points), somewhat dissatisfied (50 points), and very dissatisfied (25 
points). The scale is calculated by taking an unweighted average over these four questions 
providing a score ranging from 25 to 100 (with 100 being most satisfied). This will be treated 
as a continuous variable in analysis. 
 
• Body Map  
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The body map in Section M of the questionnaire is used to determine chronic widespread 
pain according to Manchester’s definition CWP(M). Patients indicate sections of the body 
where they feel pain by shading in sections of a mannequin (viewed from front, back, left 
and right) and the Manchester definition is used to categorise patients into those who have 
CWP(M) and those who do not. To satisfy the Manchester definition of chronic widespread 
pain [CWP(M)], pain must be reported in at least two sections of each two contralateral 
limbs and in the axial skeleton and have been present for at least 3 months. Although the 
presence of pain for 3 month is not recorded in the trial, we will classify patients based on 
the other elements of the definition. 
4.3. Procedures for missing data 
 
In all tables missing data will be indicated by footnotes. If the amount of missing data differs 
substantially between treatment groups potential reasons will be explored. Sensitivity 
analyses will be conducted (including the use of multiple imputation by chained equations 
(mice) methods) to examine the influence of missing data on the key trial findings. When 
using mice, 25 datasets will be generated and 10 switching procedures undertaken. The 
imputation model will include all variables predictive of missingness, together with all of the 
variables included in the main substantive model. Comparisons of results from ITT analyses 
of complete cases with ITT analyses where missing data were imputed will be presented in 
Table 20 - Table 32. 
 
The model used for imputation will include a baseline measure of the outcome, any other 
observations of the outcome at different follow-up times, randomisation group, age/gender, 
centre and any other restriction variables for the randomisation (i.e. stratification/ 
minimisation), we will consider also including any other variables that are either strongly 
associated with missingness or likely to have some prognostic value. This list will be finalised 
before conducting the mice analyses.  
 
In the event of missing data, we will follow guidelines where applicable and use mice to 
impute scores if the missingness exceeds the guidelines.  
 
BPI (severity and interference): The first four items of section A must be complete to 
calculate the score for the severity scale. Four of the last seven items of section A of the 
questionnaire must be complete to calculate the interference scale by averaging complete 
items.  
 
OKS: If 1 or 2 questions are missing, then the mean value can be used to fill the gaps. 
 
 12 
 
PainDETECT: If any of the first seven items of section C are missing impute with the mean of 
the complete items in the first seven items. If question 8 of section C is missing do not add 
or subtract anything from the score (ie. Treat the value of that item as zero). If question 9 is 
missing, assume the response is no, thus, treat the value of the item as zero. 
 
DN-4: No score can be calculated if more than 4 items are missing. The score is a proportion 
of “Yes” responses. 
 
Short form-12: The short form-12 requires 50% of items to be completed.  
 
HADS: The score for a single missing item from a sub scale is inferred by using the mean of 
the remaining six items. If more than one item is missing from a sub scale, that sub-scale 
cannot be calculated.  
 
ICECAP-A: There is not any internal way of dealing with missing data, as each attribute on 
the questionnaire is intended to be mutually exclusive. For this trial we will fill the missing 
value with the mean of the completed items if one item is missing. If two or more items are 
missing we will impute the whole score using mice. 
 
Pain Catastrophizing Scale: There are no formal guidelines for dealing with missing data in 
the PCS. We allow one item to be missing from each subscale and this item will be replaced 
by the mean of the complete items in that subscale. If more than one item is missing from 
each subscale, we will impute the whole score using mice. 
 
Pain Solution Score: 75% of items in each subscale need to be complete in order to 
calculate a score. We extrapolate the score to new total sub-scores. For example, if 4 items 
of 5 have been completed. The total score of the 4 is divided be 4 and multiplied by 5.  
 
Satisfaction scale: There are no formal guidelines for dealing with missing data. If one item 
is missing we will fill the missing value with the mean of the completed items. If more than 
one item is missing we will impute the whole score using mice. 
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5. DESCRIPTION OF PARTICIPANT CHARACTERISTICS 
5.1. Disposition 
A flow of patients through the trial will be summarised in a CONSORT diagram (Figure 1 and 
Figure 2) that will include the eligibility, exclusion, number of patients randomised to the two 
treatment groups, loss to follow up and the number of patients analysed. 
5.2. Baseline characteristics 
Baseline questionnaires will be completed by patients. This data will be summarised in Table 
1 - Table 7.  
 
As well as the baseline outcomes, demographic variables will be summarised at baseline. 
These demographic variables include age, sex, marital status, living arrangement, ethnic 
group, a measure of deprivation and level of education. The demographic variables will be 
summarised by treatment group, trial centre and overall to inform us of the demographic of 
the trial population and to check balance between treatment groups and trial centres.  
 
6. ASSESSMENT OF TRIAL QUALITY 
6.1. Eligibility checks 
The number of patients who were assessed and were not eligible for participation in the trial 
will be described in Table 8. The STAR trial eligibility criteria have been designed to minimise 
patient risk. The reason for exclusion will also be recorded in Table 8. 
6.2. Data validation  
 
The system will incorporate data entry and validation rules to reduce data entry errors, and 
management functions to facilitate auditing and data quality assurance. We will use a 
secure, web-based data collection platform (RedCap) which will be developed, validated, 
hosted and supported by the University of Bristol. Researchers from a different trial centre 
will perform data completeness checks of data and contact patients if there is missing data 
in their questionnaires. This will reduce the amount of missing data as patients will have the 
opportunity to complete missing items over the phone. This may also be an opportunity to 
clarify any misunderstandings in the questionnaire. It is important for these telephone calls 
to be done by a member of a different trial centre team so that the researcher who phones 
the patient is unaware of the treatment group allocation.  This is intended to minimise bias.  
6.3. Trial completion   
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Completion rates of questionnaires will be recorded in Table 9 and Table 12. Withdrawals 
are summarised in Table 13 and Table 14 at different time points (6 months and 12 months) 
and the reasons for withdrawal will also be recorded in Table 13 and Table 14. 
6.4. Compliance 
 
A complier to treatment is defined as a patient who attends the assessment clinic. Since 
non-compliance numbers are likely to be low, we set a rule to decide if we will use CACE 
analysis. If compliance close to 100% then ITT analysis will be very similar to CACE analysis 
and will not be informative.  
 
If compliance is greater or equal to 95% we should rule out the need for using CACE analysis. 
For compliance between 85% and 95% we will consider carrying out CACE analysis 
depending on the extent and pattern of adherence. For compliance below 85% we will use 
CACE analysis. Compliance rate will be recorded in Figure 2. 
 
Compliance is recorded in Table 48 by site and in total.  
 
6.5. Protocol deviations 
 
When identified, protocol deviations will be detailed on the appropriate standardised form 
and stored in the CRF [protocol deviation form]. The form will also be scanned and sent to 
the co-ordinating centre for review by the Chief Investigator. All protocol deviations will be 
reported to the Trial Steering Committee at meetings. 
Number of protocol deviations and their nature will be recorded overall, over trial centre 
and over treatment group. This will be presented in Table 15 - Table 16. 
 
6.6. Specify & justify changes made to the planned statistical analyses 
 
Any adjustment to the statistical analysis plan will be logged in Table 52.  
 
7. ANALYSIS OF EFFECTIVENESS 
7.1 Statistical analysis 
STATA will be used for all statistical analysis.  
 
Continuous variables will be summarised using the mean and standard deviation (SD) (or 
median and inter quartile range (IQR) if the distribution is skewed), and categorical data will 
be summarised as a number and percentage. 
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7.2. Summary of primary and secondary outcomes 
The primary and main secondary analyses will be conducted using the ITT principle using the 
appropriate regression model. Assumptions for each regression will be checked to make 
sure the correct method of analysis is being used. A summary of the primary and secondary 
outcomes can be seen in Table 17. 
7.3. Primary analysis 
Each of the co-primary outcome measures, BPI Severity and BPI Interference scales, will be 
analysed to compare treatment groups using linear regression. The models will be adjusted 
for trial centre as a fixed effect and baseline BPI pain scores. Estimates will be calculated of 
the effect that intervention has on each of the BPI scores compared to usual care.  
 
Results from the primary analysis will be presented in Table 18. 
7.4. Secondary analyses 
The secondary outcomes will be analysed using appropriate regression models in a similar 
manner to the primary analysis. The models will adjust for trial centre, baseline BPI pain 
score and also the baseline scores of the outcome for which it is modelling. A summary of 
the primary and secondary outcomes can be seen in Table 17. 
 
Results from the secondary analysis will be presented in Table 19. 
 
7.5. Model assumptions and Model Fit  
 
For the above analyses, the following assumptions must be satisfied for the regression 
models to provide trustworthy results.  
 
Assumptions for Linear regression: 
1. Continuous outcome variable. 
2. One or more explanatory variables, can be categorical or continuous.  
3. Linear relationship between each explanatory variable vs. Pain score – To be checked 
using a scatter plot of the outcome variable and each explanatory variable in turn. 
4. Homoscedasticity - to be checked using plots of residuals. 
5. Normally distributed outcome variable – To be checked with a histogram and a Q-Q 
plot. If data is not normally distributed we will consider the appropriateness of using 
a log transformation. 
6. No or little multicollinearity – We will verify the associations between explanatory 
variables using contingency tables and correlation coefficients as appropriate.  
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We will also check for multi-collinearity in our logistic regression models in the same 
manner. 
 
Assumptions for Logistic regression: 
1. Dichotomous outcome variable (eg, CWP(M) status: Y/N). 
2. One or more explanatory variable.  
3. Independent observations (The same patient cannot be recruited twice).  
4. Linear relationship between the continuous explanatory variables and the logistic 
transformation of the outcome variables – To be checked using a scatter plot of the 
outcome variable and each explanatory variable in turn. 
 
Model fit for linear regression models will be assessed by comparing the observed values to 
the fitted values produced by the model. These will be presented on a plot of observed 
values against fitted values. If the model does not fit well, log transformations will be tested 
to see if this makes a difference to the quality of model fit. 
 
 
 
7.6. Sensitivity analysis 
 
We will investigate the influence of missing data using sensitivity analyses that make 
different assumptions, such as “best” and “worst” case scenarios, as well as using multiple 
imputation by chained equation (mice) to impute missing data.  
 
7.6.1 Overlap  
 
A small number of patients (≤15) who are involved in the STAR trial may also be involved in 
another trial and thus may influence one or both trials results. We will not have enough 
power to sensibly investigate if an interaction between outcome and involvement in both 
trials is present. Thus, we will record which patients are involved in both trials and a 
sensitivity analysis will be performed as a repeat of the primary analysis on patients who are 
only involved in STAR.  
 
Patient burden is an issue which will be addressed in recruitment of the STAR trial. To avoid 
increased drop-out rate among patients involved in both trials the requirements of the 
patient, in terms of questionnaires and follow-up, will be made very clear.  Patients will also 
be informed that the two trials are separate trials and declining participation in one will not 
affect participation in the other.  
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Sensitivity analysis results for the primary outcomes to deal with any potential overlap will 
be presented in Table 35 and Table 36. 
 
7.6.2 Per protocol and CACE analysis 
 
We propose to carry out per protocol analyses. It will only compare individuals who 
remained in their allocated treatment group throughout the trial. Since this analysis is likely 
to be biased, we will also use the Complier Average Causal Effect (CACE) approach if the 
quantity of compliant patients (those patients in the intervention group who attend their 
initial assessment clinic and those in the control arm who continue with usual care) satisfies 
the rule which we state in section 6.4. Compliance. This provides an unbiased estimate for 
the treatment effect for those who have complied with the treatment group allocation. 
Compliers would be defined as a patient who attends the assessment clinic (intervention). 
This approach would be justified if the characteristics of those who adhered to the 
comparator treatment differed from those that adhered to the intervention. Results from 
these analyses will be presented as in Table 35 - Table 47. If there is differential adherence 
in the two arms we will also investigate structural mean approaches as described by Fischer 
et al  (Fischer, Goetghebeur, Vrijens, & White, 2011) and, separately, use extensions of CACE 
as described by White et al (White, Kalaitzaki, & Thompson, 2011) 
 
7.7. Exploratory/other analysis 
We recognise that there will be low power for sub group and exploratory analyses and 
therefore only cautious conclusions will be drawn from them. 
7.7.1 Exploratory analysis 
Exploratory analyses such as CACE methodology will be used to estimate the effect in those 
patients able to comply with their allocated intervention. 
7.7.2 Subgroup analysis  
Subgroup analyses will be performed by introducing appropriate interaction terms between 
the intervention group and other patient characteristics in the regression models, to 
investigate any differential effects in certain subgroups of the population. These factors will 
be trial centre and baseline Oxford Knee Score. The OKS will be treated as a continuous 
variable ranging 0-48, however, for descriptive purposes we will consider the conventional 
categories of 0-19 (severe knee arthritis); 20-19 (moderate to severe knee arthritis); 30-39 
(moderate knee arthritis) and 40-48 (satisfactory joint function). 
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7.7.3 Trial Centre Effect  
Trial centre will be included in the regression models as a fixed effect to analyse the 
outcome measures. This will inform us of the effect that the trial centre has on each 
outcome.  
 
 
8. ANALYSIS OF SAFETY 
8.1. Adverse reactions 
 
Data on adverse reactions and serious adverse reactions will also be collected and closely 
monitored to ensure the ongoing safety of participants. Adverse reactions will be recorded 
on a standardised adverse reactions report form (adverse reactions report form). All serious 
adverse reactions will be notified to the trial sponsor (North Bristol NHS Trust) and reviewed 
by the Trial Steering Committee. Data on adverse reactions will be collected from trial 
questionnaires and during telephone contact with participants. Numbers of adverse 
reactions and their severity will be recorded in Table 49. Details of the adverse reactions will 
be presented in Table 50 and Table 51. 
 
Please refer to the trial protocol, section titled “Adverse Event Management” 
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9. FINAL REPORT TABLES AND FIGURES 
 
Figure 1: Consort flow diagram to monitor the number or patients included in the trial up to randomisation 
Number assessed for eligibility (Completed and returned 
screening questionnaires) N= 
 
Not eligible to take part 
N= 
Reason 1) N= 
Reason 2) N= 
Reason 3) N= 
 
Phone call 3-5 days after the trial information pack is 
posted. Complete a telephone OKS with the patient to 
patient to ensure they still meet the inclusion criteria for 
the trial. 
Potentially eligible to take part. Sent a trial information 
pack by the local researcher. (OKS ≤ 14) 
N= 
 
Eligible to take part N= 
(Eligibility proforma). 
 
No longer eligible to take part N= 
Explained on the phone and sent a 
thank you letter (trial ineligibility 
letter) 
Reason 1) N= 
Reason 2) N= 
Reason 3) N= 
 
Not consented: Not recorded N= 
Reason 1) N= 
Reason 2) N= 
Reason 3) N= 
 
Face-to-face appointment - patient decides they would 
like to participate in the trial  
Randomisation  
N= 
 
Written informed consent obtained 
N= 
Intervention arm  
N= 
Control arm 
N= 
 
Number screened (Screening questionnaire) 
N= 
  
Not responded (eligibility 
unknown) 
N= 
Drop-out  
N=  
Reason 1) N= 
Reason 2) N= 
Reason 3) N= 
 
Baseline questionnaire completed 
N= 
  
Baseline data not obtained 
N= 
 Reason 1) N= 
Reason 2) N= 
Reason 3) N= 
  
Not consented: Recorded N= 
Reason 1) N= 
Reason 2) N= 
Reason 3) N= 
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Figure 2: Consort diagram to monitor the number of patients included in the trial post randomisation
Randomisation  
N= 
 
Intervention arm  
N= 
Control arm 
N= 
 
Loss to follow up 
N= 
 Reason 1) N= 
Reason 2) N= 
Reason 3) N= 
 
6 Months 
questionnaire 
N= 
 
Loss to follow up  
N= 
 Reason 1) N= 
Reason 2) N= 
Reason 3) N= 
  
6 Months 
questionnaire 
N= 
  
Loss to follow up 
N= 
 Reason 1) N= 
Reason 2) N= 
Reason 3) N= 
  
12 Months 
questionnaire 
N= 
  
Loss to follow up  
N= 
 Reason 1) N= 
Reason 2) N= 
Reason 3) N= 
  
12 Months 
questionnaire 
N= 
  
Compliance (%)  
=  
 21 
 
 
Figure 3: flow diagram to show the number of patients to receive each treatment which the intervention leads to 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Number of patient receiving one referral   
Number of patient receiving two referral  
Number of patient receiving three referral  
…  
Number of patients in the intervention arm1 
N= 
N= 
Surgeon 
referral 
N= 
GP referral 
N= 
Pain clinic referral because 
of CRPS (via GP) 
N= 
Referral to 
physiotherapy 
N= 
Follow-up to 
monitor pain  
N= 
Other, 
please 
specify 
N= 
Because of: 
1) Infection N= 
2) Malalignment N= 
3) Stiffness N= 
4) Patellofemoral 
joint problems N= 
5) Instability N= 
Because of: 
1) Depression   
N= 
2) Anxiety 
N= 
3) Neuropathic pain 
N= 
 
Because of: 
1) Stiffness  
N= 
2) Pain that has 
origins in the hip 
or elsewhere 
N= 
3) Other reasons 
N= 
 
Reasons: 
1) Reason 1: 
N= 
2) Reason 2: 
N= 
3) Reason 3: 
N= 
4) Reason 4: 
N= 
 22 
 
Tables 
9.1. Subject characteristics and baseline summaries 
 
Table 1: Baseline statistics for participants overall. 
Demographic Variables        
 N # Missing mean s.d. min med max 
Age        
 N Number of Male (%) Number of Female (%) 
Sex    
 
N Single (%) Married/ partner 
(%) 
Divorced/ separated 
(%) 
Widowed 
(%) 
Other (%) 
Marital Status       
 
N Alone (%) With husband/ 
wife/ Partner (%) 
With Somebody 
else (%) 
Other (%) 
Living arrangement      
 N White (%) Mixed (%) Asian (%) Black (%) Chinese (%) Other (%) 
Ethnic Group         
Outcome Measures         
 N # Missing mean s.d. min med max 
BPI Severity        
BPI Interference        
OKS        
DN-4        
PainDETECT        
Pain Catastrophizing scale        
PaSol: Solving Pain        
PaSol: Meaningful life        
PaSol: Acceptance of pain        
PaSol: Belief in solution        
Patient Satisfaction        
ICECAP-A        
Short form-12        
 N Number of “Normal” (%) # “Borderline” (%)  # “Clinical” (%) 
HADS: Anxiety     
HADS: Depression     
 
N # “Rarely” 
(%) 
# “Sometimes” 
(%) 
# “Often” 
(%) 
# “Most of the time” 
(%) 
# “All of the 
time” (%) 
Section A: Question 5       
Section D: Question 8       
 
N # “Much 
Better” 
(%) 
# “A bit better” 
(%) 
# “The 
same” (%) 
# “A bit worse” (%) # “Much 
worse” (%) 
Section L: Question 5       
 N # CWP(M) positive (%) # CWP(M) negative (%) 
Body Map (CWP(M))    
 
 
Table 2: Baseline statistics for Bristol 
Demographic Variables        
 N # Missing mean s.d. min med max 
Age        
 N Number of Male (%) Number of Female (%) 
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Sex    
 
N Single (%) Married/ partner 
(%) 
Divorced/ separated 
(%) 
Widowed 
(%) 
Other (%) 
Marital Status       
 
N Alone (%) With husband/ 
wife/ Partner (%) 
With Somebody 
else (%) 
Other (%) 
Living arrangement      
 N White (%) Mixed (%) Asian (%) Black (%) Chinese (%) Other (%) 
Ethnic Group         
Outcome Measures         
 N # Missing mean s.d. min med max 
BPI Severity        
BPI Interference        
OKS        
DN-4        
PainDETECT        
Pain Catastrophizing scale        
PaSol: Solving Pain        
PaSol: Meaningful life        
PaSol: Acceptance of pain        
PaSol: Belief in solution        
Patient Satisfaction        
ICECAP-A        
Short form-12        
 N Number of “Normal” (%) # “Borderline” (%)  # “Clinical” (%) 
HADS: Anxiety     
HADS: Depression     
 
N # “Rarely” 
(%) 
# “Sometimes” 
(%) 
# “Often” 
(%) 
# “Most of the time” 
(%) 
# “All of the 
time” (%) 
Section A: Question 5       
Section D: Question 8       
 
N # “Much 
Better” 
(%) 
# “A bit better” 
(%) 
# “The 
same” (%) 
# “A bit worse” (%) # “Much 
worse” (%) 
Section L: Question 5       
 N # CWP(M) positive (%) # CWP(M) negative (%) 
Body Map (CWP(M))    
 
Table 3: Baseline statistics for Cardiff 
Demographic Variables        
 N # Missing mean s.d. min med max 
Age        
 N Number of Male (%) Number of Female (%) 
Sex    
 
N Single (%) Married/ partner 
(%) 
Divorced/ separated 
(%) 
Widowed 
(%) 
Other (%) 
Marital Status       
 
N Alone (%) With husband/ 
wife/ Partner (%) 
With Somebody 
else (%) 
Other (%) 
Living arrangement      
 N White (%) Mixed (%) Asian (%) Black (%) Chinese (%) Other (%) 
Ethnic Group         
Outcome Measures         
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 N # Missing mean s.d. min med max 
BPI Severity        
BPI Interference        
OKS        
DN-4        
PainDETECT        
Pain Catastrophizing scale        
PaSol: Solving Pain        
PaSol: Meaningful life        
PaSol: Acceptance of pain        
PaSol: Belief in solution        
Patient Satisfaction        
ICECAP-A        
Short form-12        
 N Number of “Normal” (%) # “Borderline” (%)  # “Clinical” (%) 
HADS: Anxiety     
HADS: Depression     
 
N # “Rarely” 
(%) 
# “Sometimes” 
(%) 
# “Often” 
(%) 
# “Most of the time” 
(%) 
# “All of the 
time” (%) 
Section A: Question 5       
Section D: Question 8       
 
N # “Much 
Better” 
(%) 
# “A bit better” 
(%) 
# “The 
same” (%) 
# “A bit worse” (%) # “Much 
worse” (%) 
Section L: Question 5       
 N # CWP(M) positive (%) # CWP(M) negative (%) 
Body Map (CWP(M))    
 
Table 4: Baseline statistics for Oxford 
Demographic Variables        
 N # Missing mean s.d. min med max 
Age        
 N Number of Male (%) Number of Female (%) 
Sex    
 
N Single (%) Married/ partner 
(%) 
Divorced/ separated 
(%) 
Widowed 
(%) 
Other (%) 
Marital Status       
 
N Alone (%) With husband/ 
wife/ Partner (%) 
With Somebody 
else (%) 
Other (%) 
Living arrangement      
 N White (%) Mixed (%) Asian (%) Black (%) Chinese (%) Other (%) 
Ethnic Group         
Outcome Measures         
 N # Missing mean s.d. min med max 
BPI Severity        
BPI Interference        
OKS        
DN-4        
PainDETECT        
Pain Catastrophizing scale        
PaSol: Solving Pain        
PaSol: Meaningful life        
PaSol: Acceptance of pain        
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PaSol: Belief in solution        
Patient Satisfaction        
ICECAP-A        
Short form-12        
 N Number of “Normal” (%) # “Borderline” (%)  # “Clinical” (%) 
HADS: Anxiety     
HADS: Depression     
 
N # “Rarely” 
(%) 
# “Sometimes” 
(%) 
# “Often” 
(%) 
# “Most of the time” 
(%) 
# “All of the 
time” (%) 
Section A: Question 5       
Section D: Question 8       
 
N # “Much 
Better” 
(%) 
# “A bit better” 
(%) 
# “The 
same” (%) 
# “A bit worse” (%) # “Much 
worse” (%) 
Section L: Question 5       
 N # CWP(M) positive (%) # CWP(M) negative (%) 
Body Map (CWP(M))    
 
 
Table 5: Baseline statistics for Exeter 
Demographic Variables        
 N # Missing mean s.d. min med max 
Age        
 N Number of Male (%) Number of Female (%) 
Sex    
 
N Single (%) Married/ partner 
(%) 
Divorced/ separated 
(%) 
Widowed 
(%) 
Other (%) 
Marital Status       
 
N Alone (%) With husband/ 
wife/ Partner (%) 
With Somebody 
else (%) 
Other (%) 
Living arrangement      
 N White (%) Mixed (%) Asian (%) Black (%) Chinese (%) Other (%) 
Ethnic Group         
Outcome Measures         
 N # Missing mean s.d. min med max 
BPI Severity        
BPI Interference        
OKS        
DN-4        
PainDETECT        
Pain Catastrophizing scale        
PaSol: Solving Pain        
PaSol: Meaningful life        
PaSol: Acceptance of pain        
PaSol: Belief in solution        
Patient Satisfaction        
ICECAP-A        
Short form-12        
 N Number of “Normal” (%) # “Borderline” (%)  # “Clinical” (%) 
HADS: Anxiety     
HADS: Depression     
 
N # “Rarely” 
(%) 
# “Sometimes” 
(%) 
# “Often” 
(%) 
# “Most of the time” 
(%) 
# “All of the 
time” (%) 
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Section A: Question 5       
Section D: Question 8       
 
N # “Much 
Better” 
(%) 
# “A bit better” 
(%) 
# “The 
same” (%) 
# “A bit worse” (%) # “Much 
worse” (%) 
Section L: Question 5       
 N # CWP(M) positive (%) # CWP(M) negative (%) 
Body Map (CWP(M))    
 
Table 6: Baseline statistics for patients in the intervention group 
Demographic Variables        
 N # Missing mean s.d. min med max 
Age        
 N Number of Male (%) Number of Female (%) 
Sex    
 
N Single (%) Married/ partner 
(%) 
Divorced/ separated 
(%) 
Widowed 
(%) 
Other (%) 
Marital Status       
 
N Alone (%) With husband/ 
wife/ Partner (%) 
With Somebody 
else (%) 
Other (%) 
Living arrangement      
 N White (%) Mixed (%) Asian (%) Black (%) Chinese (%) Other (%) 
Ethnic Group         
Outcome Measures         
 N # Missing mean s.d. min med max 
BPI Severity        
BPI Interference        
OKS        
DN-4        
PainDETECT        
Pain Catastrophizing scale        
PaSol: Solving Pain        
PaSol: Meaningful life        
PaSol: Acceptance of pain        
PaSol: Belief in solution        
Patient Satisfaction        
ICECAP-A        
Short form-12        
 N Number of “Normal” (%) # “Borderline” (%)  # “Clinical” (%) 
HADS: Anxiety     
HADS: Depression     
 
N # “Rarely” 
(%) 
# “Sometimes” 
(%) 
# “Often” 
(%) 
# “Most of the time” 
(%) 
# “All of the 
time” (%) 
Section A: Question 5       
Section D: Question 8       
 
N # “Much 
Better” 
(%) 
# “A bit better” 
(%) 
# “The 
same” (%) 
# “A bit worse” (%) # “Much 
worse” (%) 
Section L: Question 5       
 N # CWP(M) positive (%) # CWP(M) negative (%) 
Body Map (CWP(M))    
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Table 7: Baseline statistics for patients in the control group 
Demographic Variables        
 N # Missing mean s.d. min med max 
Age        
 N Number of Male (%) Number of Female (%) 
Sex    
 
N Single (%) Married/ partner 
(%) 
Divorced/ separated 
(%) 
Widowed 
(%) 
Other (%) 
Marital Status       
 
N Alone (%) With husband/ 
wife/ Partner (%) 
With Somebody 
else (%) 
Other (%) 
Living arrangement      
 N White (%) Mixed (%) Asian (%) Black (%) Chinese (%) Other (%) 
Ethnic Group         
Outcome Measures         
 N # Missing mean s.d. min med max 
BPI Severity        
BPI Interference        
OKS        
DN-4        
PainDETECT        
Pain Catastrophizing scale        
PaSol: Solving Pain        
PaSol: Meaningful life        
PaSol: Acceptance of pain        
PaSol: Belief in solution        
Patient Satisfaction        
ICECAP-A        
Short form-12        
 N Number of “Normal” (%) # “Borderline” (%)  # “Clinical” (%) 
HADS: Anxiety     
HADS: Depression     
 
N # “Rarely” 
(%) 
# “Sometimes” 
(%) 
# “Often” 
(%) 
# “Most of the time” 
(%) 
# “All of the 
time” (%) 
Section A: Question 5       
Section D: Question 8       
 
N # “Much 
Better” 
(%) 
# “A bit better” 
(%) 
# “The 
same” (%) 
# “A bit worse” (%) # “Much 
worse” (%) 
Section L: Question 5       
 N # CWP(M) positive (%) # CWP(M) negative (%) 
Body Map (CWP(M))    
 
9.2. Trial quality summaries 
 
Table 8:  Eligibility summary 
 # screened 
patients 
# eligible to 
participate  
Eligibility rate  Reasons for ineligibility  
Bristol     
Cardiff     
Exeter     
Oxford     
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Overall     
 
 
Table 9: Questionnaire completion summary over trial centres (BASELINE). 
  # questionnaires completed sufficiently to produce outcome measure 
  Bristol  Cardiff Exeter Oxford 
 # questionnaires 
administered 
N % N % N % N % 
BPI Severity          
BPI Interference 
         
OKS          
PainDETECT          
DN-4          
Patient Satisfaction 
         
Short form-12          
HADS          
ICECAP-A          
Pain Catastrophizing 
scale 
         
Pain Solution 
Questionnaire 
         
Body Map (CWP(M)) 
         
 
Table 10: Questionnaire completion summary over trial centres (6 MONTH). 
  # questionnaires completed sufficiently to produce outcome measure 
  Bristol  Cardiff Exeter Oxford 
 # questionnaires 
administered 
N % N % N % N % 
BPI Severity          
BPI Interference 
         
OKS          
PainDETECT          
DN-4          
Patient Satisfaction 
         
Short form-12          
HADS          
ICECAP-A          
Pain Catastrophizing 
scale 
         
Pain Solution 
Questionnaire 
         
Body Map (CWP(M)) 
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Table 11: Questionnaire completion summary over trial centres (12 MONTH). 
  # questionnaires completed sufficiently to produce outcome measure 
  Bristol  Cardiff Exeter Oxford 
 # questionnaires 
administered 
N % N % N % N % 
BPI Severity          
BPI Interference 
         
OKS          
PainDETECT          
DN-4          
Patient Satisfaction 
         
Short form-12          
HADS          
ICECAP-A          
Pain Catastrophizing 
scale 
         
Pain Solution 
Questionnaire 
         
Body Map (CWP(M)) 
         
 
 
Table 12: Questionnaire completion summary treatment groups. 
  # questionnaires completed sufficiently to 
produce outcome measure 
  Intervention Control 
 # questionnaires 
administered 
N % N % 
BPI Severity      
BPI Interference 
     
OKS      
PainDETECT      
DN-4      
Patient Satisfaction 
     
Short form-12      
HADS      
ICECAP-A      
Pain 
Catastrophizing 
scale 
     
Pain Solution 
Questionnaire 
     
Body Map 
(CWP(M)) 
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Table 13: Withdrawal summary over trial centre 
 # patients 
randomised 
# withdrawals 
at 6 months 
N(%) 
# withdrawals 
at 12 month 
N(%) 
Reasons for withdrawals 
Bristol     
Cardiff     
Exeter     
Oxford     
Overall     
 
 
Table 14: Withdrawal summary over treatment group 
 # patients 
randomised 
# withdrawals 
prior to 
randomisation 
# withdrawals 
by 6 months  
# withdrawals 
by 12 month  
Reasons for withdrawals 
Intervention      
Control      
Overall      
 
 
Table 15: Number of Protocol deviations 
 Site  
 Bristol Cardiff Exeter Oxford Total 
Intervention      
Control      
Total      
 
 
Table 16: Protocol deviations 
Protocol deviation Site Intervention/ Control 
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9.3. Outcome summaries 
Table 17: Primary and Secondary endpoint summary 
Outcome measure Type of data Range of values Regression model Efficacy parameters  
BPI – Pain severity scale Continuous 0-10 (best to worst) Linear regression Mean/Median/Log mean score 
BPI – Pain Interference scale Continuous 0-10 (best to worst) Linear regression Mean/Median/Log mean score 
Oxford Knee Score (OKS) Continuous 0-48 (worst to best) Linear regression Mean/Median/Log mean score 
Douleur Neuropathique 4 (DN-4) Continuous 0-7 (best to worst) Linear regression Mean/Median/Log mean score 
PainDETECT Continuous -1-38 (best to worst) Linear regression Mean/Median/Log mean score 
Hospital Anxiety and Depression 
Scale (HADS) 
Ordinal Each subscale: 
0-21 (best to worst) 
normal score (0-7); borderline anxiety/depression (8-10) 
and clinical anxiety/depression (≥11) 
Linear regression with dummy 
variables 
Mean/Median/Log mean score 
Pain Catastrophizing Scale Continuous The Rumination Scale: 0-16 (best to worst) 
The Magnification Scale: 0-12 (best to worst) 
The Helplessness Scale: 0-24 (best to worst) 
Whole score: 0-52 (best to worst) 
Linear regression Mean/Median/Log mean score 
Pain Solution Questionnaire (PaSol) Continuous Solving Pain: 0-24 (worst to best) 
Meaningfulness of Life despite Pain: 0-30 (worst to best) 
Acceptance of Insolubility of Pain: 0-18 (worst to best) 
Belief in Solution: 0-12 (worst to best) 
Linear regression Mean/Median/Log mean score 
Self-Administered Patient 
Satisfaction Scale for Primary Hip and 
Knee Arthroplasty 
Continuous 25-100 
(worst to best) 
Linear regression Mean/Median/Log mean score 
ICECAP-A Continuous -0.001 to 1 (worst to best) Linear regression Mean/Median/Log mean score 
Short Form-12 Continuous  Linear regression Mean/Median/Log mean score 
Body Map Binary 0/1: CWP(M) or not Logistic regression Odds ratio  
Q5 Section A Ordinal “Rarely”, “Sometimes”, “Often”, “Most of the time”, “All 
of the time” 
Linear regression with dummy 
variables 
Mean/Median/Log mean score 
Q8 Section D Ordinal “Rarely”, “Sometimes”, “Often”, “Most of the time”, “All 
of the time” 
Linear regression with dummy 
variables 
Mean/Median/Log mean score 
Q5 Section L Ordinal “Much better”, “A bit better”, “The same”, “A bit 
worse”, “Much worse” 
Linear regression with dummy 
variables 
Mean/Median/Log mean score 
Resourse use Used by Health Economics 
EQ-5D-5L Used by Health Economics 
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9.4. Primary outcome results 
 
Table 18: Primary outcome table 
 N Mean SD Difference in 
means1 
95% CI P-value 
BPI Severity       
BPI Interference       
1 Adjusted for trial centre and baseline OKS 
 
 
9.5. Secondary outcomes results 
 
Table 19: Secondary outcomes tables 
 N Mean SD Difference in 
means1 
95% CI P-value 
BPI Severity       
BPI Interference       
OKS       
DN-4       
PainDETECT       
Pain Catastrophizing scale       
PaSol: Solving Pain       
PaSol: Meaningful life       
PaSol: Acceptance of pain       
PaSol: Belief in solution       
Patient Satisfaction       
ICECAP-A       
Short form-12       
HADS: Anxiety       
HADS: Depression       
Section A: Question 5       
Section D: Question 8       
Section L: Question 5       
 N Odds ratio1 95% CI P-value 
Body Map (CWP(M))     
1 Adjusted for trial centre and baseline OKS 
 
 
 
9.6. Sensitivity analysis for primary endpoint  
Comparison of results of ITT analysis of complete cases with ITT analysis where missing data were imputed 
using “best” and “worst” case scenarios and the method of MICE for primary outcome of BPI Severity Score. 
Table 20:Sensitivity analysis for missing data 
 N Difference in meansa 95% CI p-value 
Complete case     
“Best” case scenario     
“Worst” case scenario     
MICE     
a Adjusted for trial centre and for baseline OKS  
 
Comparison of results of ITT analysis of complete cases with ITT analysis where missing data were imputed 
using “best” and “worst” case scenarios and the method of MICE for primary outcome of BPI Interference 
Score. 
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Table 21: Sensitivity analysis for missing data 
 N Difference in meansa 95% CI p-value 
Complete case     
“Best” case scenario     
“Worst” case scenario     
MICE     
a Adjusted for trial centre and for baseline OKS  
 
 
 
9.7. Sensitivity analysis for secondary endpoints  
Comparison of results of ITT analysis of complete cases with ITT analysis where missing data were imputed 
using “best” and “worst” case scenarios and the method of MICE for Secondary outcome of OKS. 
Table 22: Sensitivity analysis secondary endpoint results 
 N Difference in meansa 95% CI p-value 
Complete case     
“Best” case scenario     
“Worst” case scenario     
MICE     
a Adjusted for trial centre and for baseline OKS  
 
Comparison of results of ITT analysis of complete cases with ITT analysis where missing data were imputed 
using “best” and “worst” case scenarios and the method of MICE for Secondary outcome of DN-4. 
Table 23: Sensitivity analysis secondary endpoint results 
 N Difference in meansa 95% CI p-value 
Complete case     
“Best” case scenario     
“Worst” case scenario     
MICE     
a Adjusted for trial centre and for baseline OKS  
 
Comparison of results of ITT analysis of complete cases with ITT analysis where missing data were imputed 
using “best” and “worst” case scenarios and the method of MICE for Secondary outcome of PainDETECT. 
Table 24: Sensitivity analysis secondary endpoint results 
 N Difference in meansa 95% CI p-value 
Complete case     
“Best” case scenario     
“Worst” case scenario     
MICE     
a Adjusted for trial centre and for baseline OKS  
 
Comparison of results of ITT analysis of complete cases with ITT analysis where missing data were imputed 
using “best” and “worst” case scenarios and the method of MICE for Secondary outcome of Pain 
Catastrophizing Scale. 
Table 25: Sensitivity analysis secondary endpoint results 
 N Difference in meansa 95% CI p-value 
Complete case     
“Best” case scenario     
“Worst” case scenario     
MICE     
a Adjusted for trial centre and for baseline OKS  
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Comparison of results of ITT analysis of complete cases with ITT analysis where missing data were imputed 
using “best” and “worst” case scenarios and the method of MICE for Secondary outcome of Pain Solution 
Questionnaire (PaSol). 
Table 26: Sensitivity analysis secondary endpoint results 
 N Difference in meansa 95% CI p-value 
Complete case     
“Best” case scenario     
“Worst” case scenario     
MICE     
a Adjusted for trial centre and for baseline OKS  
 
Comparison of results of ITT analysis of complete cases with ITT analysis where missing data were imputed 
using “best” and “worst” case scenarios and the method of MICE for Secondary outcome of Self-Administered 
Patient Satisfaction Scale for Primary Hip and Knee Arthroplasty. 
Table 27: Sensitivity analysis secondary endpoint results 
 N Difference in meansa 95% CI p-value 
Complete case     
“Best” case scenario     
“Worst” case scenario     
MICE     
a Adjusted for trial centre and for baseline OKS  
 
 
Comparison of results of ITT analysis of complete cases with ITT analysis where missing data were imputed 
using “best” and “worst” case scenarios and the method of MICE for Secondary outcome of ICECAP-A. 
Table 28: Sensitivity analysis secondary endpoint results 
 N Difference in meansa 95% CI p-value 
Complete case     
“Best” case scenario     
“Worst” case scenario     
MICE     
a Adjusted for trial centre and for baseline OKS  
 
Comparison of results of ITT analysis of complete cases with ITT analysis where missing data were imputed 
using “best” and “worst” case scenarios and the method of MICE for Secondary outcome of Short form-12. 
Table 29: Sensitivity analysis secondary endpoint results 
 N Difference in meansa 95% CI p-value 
Complete case     
“Best” case scenario     
“Worst” case scenario     
MICE     
a Adjusted for trial centre and for baseline OKS  
 
Comparison of results of ITT analysis of complete cases with ITT analysis where missing data were imputed 
using “best” and “worst” case scenarios and the method of MICE for Secondary outcome of Hospital Anxiety 
Scale (HADS: Anxiety).  
Table 30: Sensitivity analysis secondary endpoint results 
 N Difference in meansa 95% CI p-value 
Complete case     
“Best” case scenario     
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“Worst” case scenario     
MICE     
a Adjusted for trial centre and for baseline OKS  
 
Comparison of results of ITT analysis of complete cases with ITT analysis where missing data were imputed 
using “best” and “worst” case scenarios and the method of MICE for Secondary outcome of Hospital 
Depression Scale (HADS: depression).  
Table 31: Sensitivity analysis secondary endpoint results 
 N Difference in meansa 95% CI p-value 
Complete case     
“Best” case scenario     
“Worst” case scenario     
MICE     
a Adjusted for trial centre and for baseline OKS  
 
 
 
Comparison of results of ITT analysis of complete cases with ITT analysis where missing data were imputed 
using “best” and “worst” case scenarios and the method of MICE for Secondary outcome of Chronic 
Widespread Pain (Body Map). 
Table 32: Sensitivity analysis secondary endpoint results 
 N Odds Ratioa 95% CI p-value 
Complete case     
“Best” case scenario     
“Worst” case scenario     
MICE     
a Adjusted for trial centre and for baseline OKS  
 
 
Sensitivity analysis – Overlap 
 
 
Comparison of results of ITT analysis of all cases with ITT analysis where only patients involved in STAR are 
analysed for primary outcome of BPI Severity scale.  
Table 33: Overlap sensitivity analysis for BPI Severity scale 
 N Difference in meansa 95% CI p-value 
Overall ITT analysis     
Only STAR Participants     
a Adjusted for trial centre and for baseline OKS  
 
 
Comparison of results of ITT analysis of all cases with ITT analysis where only patients involved in STAR are 
analysed for primary outcome of BPI Interference scale.  
Table 34: Overlap sensitivity analysis for BPI Severity scale 
 N Difference in meansa 95% CI p-value 
Overall ITT analysis     
Only STAR Participants     
a Adjusted for trial centre and for baseline OKS  
 
8.8. Per protocol and CACE analysis  
 
Comparison of results of ITT analysis of complete cases with per protocol analysis and CACE analysis for 
primary outcome of BPI Severity Score. 
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Table 35: Sensitivity analysis for missing data 
 N Difference in meansa 95% CI p-value 
ITT     
Per protocol     
CACE analysis     
a Adjusted for trial centre and for baseline OKS  
 
Comparison of results of ITT analysis of complete cases with per protocol analysis and CACE for primary 
outcome of BPI Interference Score. 
Table 36: Sensitivity analysis for missing data 
 N Difference in meansa 95% CI p-value 
ITT     
Per protocol     
CACE analysis     
a Adjusted for trial centre and for baseline OKS  
 
 
Comparison of results of ITT analysis of complete cases with per protocol analysis and CACE for Secondary 
outcome of OKS. 
Table 37: Sensitivity analysis secondary endpoint results 
 N Difference in meansa 95% CI p-value 
ITT     
Per protocol     
CACE analysis     
a Adjusted for trial centre and for baseline OKS  
 
Comparison of results of ITT analysis of complete cases with per protocol analysis and CACE for Secondary 
outcome of DN-4. 
Table 38: Sensitivity analysis secondary endpoint results 
 N Difference in meansa 95% CI p-value 
ITT     
Per protocol     
CACE analysis     
a Adjusted for trial centre and for baseline OKS  
 
Comparison of results of ITT analysis of complete cases with per protocol analysis and CACE for Secondary 
outcome of PainDETECT. 
Table 39: Sensitivity analysis secondary endpoint results 
 N Difference in meansa 95% CI p-value 
ITT     
Per protocol     
CACE analysis     
a Adjusted for trial centre and for baseline OKS  
 
Comparison of results of ITT analysis of complete cases with per protocol analysis and CACE for Secondary 
outcome of Pain Catastrophizing Scale. 
Table 40: Sensitivity analysis secondary endpoint results 
 N Difference in meansa 95% CI p-value 
ITT     
Per protocol     
CACE analysis     
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a Adjusted for trial centre and for baseline OKS  
 
Comparison of results of ITT analysis of complete cases with per protocol analysis and CACE for Secondary 
outcome of Pain Solution Questionnaire (PaSol). 
Table 41: Sensitivity analysis secondary endpoint results 
 N Difference in meansa 95% CI p-value 
ITT     
Per protocol     
CACE analysis     
a Adjusted for trial centre and for baseline OKS  
 
Comparison of results of ITT analysis of complete cases with per protocol analysis and CACE for Secondary 
outcome of Self-Administered Patient Satisfaction Scale for Primary Hip and Knee Arthroplasty. 
Table 42: Sensitivity analysis secondary endpoint results 
 N Difference in meansa 95% CI p-value 
ITT     
Per protocol     
CACE analysis     
a Adjusted for trial centre and for baseline OKS  
 
 
Comparison of results of ITT analysis of complete cases with per protocol analysis and CACE for Secondary 
outcome of ICECAP-A. 
Table 43: Sensitivity analysis secondary endpoint results 
 N Difference in meansa 95% CI p-value 
ITT     
Per protocol     
CACE analysis     
a Adjusted for trial centre and for baseline OKS  
 
Comparison of results of ITT analysis of complete cases with per protocol analysis and CACE for Secondary 
outcome of Short form-12. 
Table 44: Sensitivity analysis secondary endpoint results 
 N Difference in meansa 95% CI p-value 
ITT     
Per protocol     
CACE analysis     
a Adjusted for trial centre and for baseline OKS  
 
Comparison of results of ITT analysis of complete cases with per protocol analysis and CACE for Secondary 
outcome of Hospital Anxiety Scale (HADS: Anxiety). 
Table 45: Sensitivity analysis secondary endpoint results 
 N Difference in meansa 95% CI p-value 
ITT     
Per protocol     
CACE analysis     
a Adjusted for trial centre and for baseline OKS  
 
 
Comparison of results of ITT analysis of complete cases with per protocol analysis and CACE for Secondary 
outcome of Hospital Depression Scale (HADS: Depression). 
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Table 46: Sensitivity analysis secondary endpoint results 
 N Difference in meansa 95% CI p-value 
ITT     
Per protocol     
CACE analysis     
a Adjusted for trial centre and for baseline OKS  
 
 
Comparison of results of ITT analysis of complete cases with per protocol analysis and CACE for Secondary 
outcome of Chronic Widespread Pain (Body Map). 
Table 47: Sensitivity analysis secondary endpoint results 
 N Odds Ratioa 95% CI p-value 
ITT     
Per protocol     
CACE analysis     
a Adjusted for trial centre and for baseline OKS  
 
 
Table 48: Compliance 
 Number of patients 
randomised to 
intervention group 
Number of patients who 
attend intervention 
appointment 
Compliance (%) 
Bristol    
Cardiff    
Exeter    
Oxford    
Total    
 
 
8.9. Safety results 
 
 
Table 49: Reporting Adverse reactions 
Relatedness to trial intervention: Frequency 
Severity: Not Serious  
Serious unexpected  
Serious expected  
 
Table 50: Adverse reactions 
Adverse reaction Site  Intervention/ 
Control 
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Table 51:  Serious Adverse reactions 
Adverse reaction Site  Intervention/ 
Control 
   
   
   
   
   
   
   
 
 
 
Amendments to the SAP 
 
 
Table 52: Amendments to the SAP 
Previous 
version 
Previous 
date 
New 
version 
New 
date 
Brief summary of changes 
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10. APPENDICES 
10.1. Stata code for derived variables 
 
*BPI_severity 
 
gen bpi_severity = (worst_bl+least_bl+average_bl+rightnow_bl)/4 
 
 
*BPI_interference  
 
gen bpi_int = 
(interfere_gen_bl+interfere_mood_bl+interfere_walk_bl+interfere_norm_bl+interfere_relation_bl+
interfere_sleep_bl+interfere_life_bl)/7 
 
 
*Oxford knee score 
 
gen oks = 
replaced_pain_bl+replaced_wash_bl+replaced_car_bl+replaced_walk_bl+replaced_sat_bl+replaced_li
mp_bl+replaced_kneel_bl+replaced_trouble_bl+replaced_work_bl+replaced_giveway_bl+replaced_shop
_bl+replaced_stairs_bl 
* OKS pain subscale 
oks_pain_raw = 
replaced_pain_bl+replaced_walk_bl+replaced_sat_bl+replaced_limp_bl+replaced_trouble_bl+replace
d_work_bl+replaced_giveway_bl+ 
oks_pain_sta = 3.57*oks_pain_raw 
*OKS function subscale 
oks_func_raw = 
replaced_wash_bl+replaced_car_bl+replaced_kneel_bl+replaced_shop_bl+replaced_stairs_bl 
oks_func_sta = 5*oks_func_raw 
 
 
*DN-4 
 
*gen yn_feelpain_burn_bl = . 
*replace yn_feelpain_burn_bl = 1 if feelpain_burn_bl = "yes" 
*replace yn_feelpain_burn_bl = 0 if feelpain_burn_bl = "no" 
 
*gen yn_feelpain_cold_bl = . 
*replace yn_feelpain_cold_bl = 1 if feelpain_cold_bl = "yes" 
*replace yn_feelpain_cold_bl = 0 if feelpain_elect_bl = "no" 
 
*gen yn_feelpain_elect_bl = . 
*replace yn_feelpain_elect_bl = 1 if feelpain_elect_bl = "yes" 
*replace yn_feelpain_elect_bl = 0 if feelpain_elect_bl = "no" 
 
*gen yn_painfeel_tingling_bl = . 
*replace yn_painfeel_tingling_bl = 1 if painfeel_tingling_bl = "yes" 
*replace yn_painfeel_tingling_bl = 0 if painfeel_tingling_bl = "no" 
 
*gen yn_painfeel_pins_bl = . 
*replace yn_painfeel_pins_bl = 1 if painfeel_pins_bl = "yes" 
*replace yn_painfeel_pins_bl = 0 if painfeel_pins_bl = "no" 
 
*gen yn_painfeel_numbness_bl = . 
*replace yn_painfeel_numbness_bl = 1 if painfeel_numbness_bl = "yes" 
*replace yn_painfeel_numbness_bl = 0 if painfeel_numbness_bl = "no" 
 
*gen yn_painfeel_itching_bl = . 
*replace yn_painfeel_itching_bl = 1 if painfeel_itching_bl = "yes" 
*replace yn_painfeel_itching_bl = 0 if painfeel_itching_bl = "no" 
 
*egen dn_4 = 
yn_feelpain_burn_bl+yn_feelpain_cold_bl+yn_feelpain_elect_bl+yn_painfeel_tingling_bl+yn_painfe
el_pins_bl+yn_painfeel_numbness_bl+yn_painfeel_itching_bl 
 
egen dn_4 = 
feelpain_burn_bl+feelpain_cold_bl+feelpain_elect_bl+painfeel_tingling_bl+painfeel_pins_bl+pain
feel_numbness_bl+painfeel_itching_bl 
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*PainDETECT 
 
gen feelpain_replaced_bl_score = . 
replace feelpain_replaced_bl_score = 0 if feelpain_replaced_bl == 1 
replace feelpain_replaced_bl_score = -1 if feelpain_replaced_bl == 2 
replace feelpain_replaced_bl_score = 1 if feelpain_replaced_bl == 3 
replace feelpain_replaced_bl_score = 1 if feelpain_replaced_bl == 4 
 
gen pain_detect = . 
replace pain_detect = 
(feelpain_sting_bl+feelpain_prick_bl+feelpain_touch_bl+feelpain_shock_bl+feelpain_temp_bl+feel
pain_numb_bl+feelpain_press_bl+feelpain_replaced_bl_score+feelpain_radiate_bl) 
 
 
*HADS 
 
gen hads_a = 
(mood_wound_bl+mood_fright_bl+mood_worry_bl+mood_relax_bl+mood_butterfly_bl+mood_restless_bl+m
ood_panic_bl) 
 
gen hads_d = 
(mood_enjoy_bl+mood_laugh_bl+mood_cheerful_bl+mood_slow_bl+mood_appear_bl+mood_lookforward_bl+
mood_book_bl) 
 
*Pain Catastrophizing Scale 
 
 
gen pcs_r = (pain_away_bl+pain_mind_bl+pain_hurts_bl+pain_stop_bl) 
 
gen pcs_m = (pain_worse_bl+pain_events_bl+pain_serious_bl) 
 
gen pcs_h = 
(pain_worry_bl+pain_can_go_on_bl+pain_terrible_bl+pain_awful_bl+pain_stand_more_bl+pain_intens
ity_bl) 
 
 
*PaSol 
 
gen pa_sol_solve = 
deal_pain_search_bl+deal_pain_rid_bl+deal_pain_solut_bl+deal_pain_without_bl 
 
gen pa_sol_meaning = 
deal_pain_meaningful_bl+deal_pain_wayout_bl+deal_pain_live_bl+deal_pain_best_bl+deal_pain_way_
bl 
 
gen pa_sol_accept = deal_pain_no_solution_bl+deal_pain_cntrl_bl+deal_pain_accept_bl 
 
gen pa_sol_belief = deal_pain_conf_bl+deal_pain_treat_bl 
 
*ICECAP-A 
 
 
 
matrix UTILS=(-0.001,0.101,0.191,0.222\/*  
*/-0.024,0.096,0.189,0.228\/* 
*/0.006, 0.084, 0.156, 0.188\/* 
*/0.021, 0.091, 0.159, 0.181\ /* 
*/ -0.003, 0.069, 0.154, 0.181) 
gen sta_index=UTILS[1,feel_settled_bl[_n]] 
gen att_index=UTILS[2,feel_love_bl[_n]] 
gen aut_index=UTILS[3,mood_indep_bl[_n]] 
gen ach_index=UTILS[4,mood_achieve_bl[_n]] 
gen enj_index=UTILS[5,mood_pleasure_bl[_n]] 
gen tariff=sta_index+att_index+aut_index+ach_index+enj_index 
 
*Satisfaction scale 
gen 
satisfaction_scale=(satisfied_surgery_bl+satis_improve_bl+satis_housework_bl+satis_leisure_bl)
/4 
 
 
*EQ-5D-5L 
*Used by KG for health econ 
 
*ShortForm-12 
*software calculated scores 
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